WO2007021494A3 - Albumin fusion proteins - Google Patents

Albumin fusion proteins Download PDF

Info

Publication number
WO2007021494A3
WO2007021494A3 PCT/US2006/029391 US2006029391W WO2007021494A3 WO 2007021494 A3 WO2007021494 A3 WO 2007021494A3 US 2006029391 W US2006029391 W US 2006029391W WO 2007021494 A3 WO2007021494 A3 WO 2007021494A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
albumin fusion
nucleic acids
vectors
host cells
Prior art date
Application number
PCT/US2006/029391
Other languages
French (fr)
Other versions
WO2007021494A2 (en
Inventor
Craig Rosen
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Craig Rosen
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig Rosen, Adam Bell, Paul Moore, Yanggu Shi, David Lafleur, Michael Laird, William Haseltine, Douglas Woods, Jason Bock, Mani Subramanian filed Critical Human Genome Sciences Inc
Priority to AU2006280312A priority Critical patent/AU2006280312A1/en
Priority to JP2008526056A priority patent/JP2009504157A/en
Priority to CA002618476A priority patent/CA2618476A1/en
Priority to EP06813242A priority patent/EP1924596A4/en
Priority to MX2008001865A priority patent/MX2008001865A/en
Priority to BRPI0614761-5A priority patent/BRPI0614761A2/en
Publication of WO2007021494A2 publication Critical patent/WO2007021494A2/en
Publication of WO2007021494A3 publication Critical patent/WO2007021494A3/en
Priority to IL189246A priority patent/IL189246A0/en
Priority to TNP2008000064A priority patent/TNSN08064A1/en
Priority to NO20081233A priority patent/NO20081233L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
PCT/US2006/029391 2005-08-12 2006-07-31 Albumin fusion proteins WO2007021494A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2006280312A AU2006280312A1 (en) 2005-08-12 2006-07-31 Albumin fusion proteins
JP2008526056A JP2009504157A (en) 2005-08-12 2006-07-31 Albumin fusion protein
CA002618476A CA2618476A1 (en) 2005-08-12 2006-07-31 Albumin fusion proteins
EP06813242A EP1924596A4 (en) 2005-08-12 2006-07-31 Albumin fusion proteins
MX2008001865A MX2008001865A (en) 2005-08-12 2006-07-31 Albumin fusion proteins.
BRPI0614761-5A BRPI0614761A2 (en) 2005-08-12 2006-07-31 albumin fusion proteins
IL189246A IL189246A0 (en) 2005-08-12 2008-02-04 Albumin fusion proteins
TNP2008000064A TNSN08064A1 (en) 2005-08-12 2008-02-11 Albumin fusion proteins
NO20081233A NO20081233L (en) 2005-08-12 2008-03-10 Albumin fusion proteins

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US60/707,521 2005-08-12
US71238605P 2005-08-31 2005-08-31
US60/712,386 2005-08-31
US73272405P 2005-11-03 2005-11-03
US60/732,724 2005-11-03
US77691406P 2006-02-28 2006-02-28
US60/776,914 2006-02-28
US78136106P 2006-03-13 2006-03-13
US60/781,361 2006-03-13
US81018206P 2006-06-02 2006-06-02
US60/810,182 2006-06-02
US81368206P 2006-06-15 2006-06-15
US60/813,682 2006-06-15

Publications (2)

Publication Number Publication Date
WO2007021494A2 WO2007021494A2 (en) 2007-02-22
WO2007021494A3 true WO2007021494A3 (en) 2007-07-26

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103525695A (en) * 2012-07-04 2014-01-22 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
CN105567699A (en) * 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 Albumin variants

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1276849A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
BRPI0507026A (en) 2004-02-09 2007-04-17 Human Genome Sciences Inc albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2068905A4 (en) * 2006-09-14 2009-12-30 Human Genome Sciences Inc Albumin fusion proteins
US7884184B2 (en) 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
JP5685529B2 (en) 2008-06-13 2015-03-18 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． Complexes for the administration of compounds having biological activity
EP2387420A2 (en) 2009-01-16 2011-11-23 Teva Pharmaceutical Industries Limited New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
JP5936112B2 (en) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ Albumin variants and complexes
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
CN102741422B (en) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 Factor VII composition and preparation and application thereof
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN103402542B (en) * 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 Medicinal agent for inhibiting metastasis of malignant tumor
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014017165B1 (en) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF
JP6256882B2 (en) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド Factor VIII composition, and method of making and use of the composition
JP6383666B2 (en) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド Recombinant factor VIII protein
BR112014018679A2 (en) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As albumin variants
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
JP2015521589A (en) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Procoagulant compounds
SG10201913893XA (en) 2012-07-11 2020-03-30 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
MX2015005363A (en) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Albumin variants.
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RS63583B1 (en) 2014-01-10 2022-10-31 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
EP3355907B1 (en) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
DK3411478T3 (en) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENES
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110337590A (en) 2016-11-04 2019-10-15 奥胡斯大学 The identification and treatment of tumour characterized by neonatal Fc receptor is overexpressed
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
MA50141A (en) * 2017-04-20 2020-07-29 Novo Nordisk As ALBUMIN FUSION PROTEIN PURIFICATION PROCESSES
CN111247251A (en) 2017-08-09 2020-06-05 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and uses thereof
BR112020015228A2 (en) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US20200199626A1 (en) 2018-12-06 2020-06-25 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JPWO2022030580A1 (en) * 2020-08-06 2022-02-10
WO2024080306A1 (en) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and physiologically-active protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277889B1 (en) * 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0507026A (en) * 2004-02-09 2007-04-17 Human Genome Sciences Inc albumin fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OSBORN B.L. ET AL.: "Pharmadinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 303, no. 2, 2002, pages 540 - 548, XP003006693 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567699A (en) * 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 Albumin variants
CN103525695A (en) * 2012-07-04 2014-01-22 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system

Also Published As

Publication number Publication date
ECSP088262A (en) 2008-05-30
MX2008001865A (en) 2008-04-15
JP2009504157A (en) 2009-02-05
NO20081233L (en) 2008-05-09
TNSN08064A1 (en) 2009-07-14
KR20080071119A (en) 2008-08-01
CA2618476A1 (en) 2007-02-22
WO2007021494A2 (en) 2007-02-22
IL189246A0 (en) 2008-08-07
EP1924596A2 (en) 2008-05-28
AU2006280312A1 (en) 2007-02-22
EP1924596A4 (en) 2009-07-29
BRPI0614761A2 (en) 2009-05-19
MA29836B1 (en) 2008-10-03

Similar Documents

Publication Publication Date Title
WO2007021494A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
EP1276756A1 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009085200A3 (en) Anti-amyloid antibodies and uses thereof
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2006017355A3 (en) Improved aprotinin variants
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2005079316A3 (en) Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof
WO2004058949A3 (en) Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
WO2003033652A3 (en) TUMOR ENDOTHELIAL MARKER 5α MOLECULES AND USES THEREOF
WO2002044379A3 (en) Transforming growth factor-beta-related molecules and uses thereof
WO2002097110A3 (en) TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680038164.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 189246

Country of ref document: IL

Ref document number: 12008500307

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2618476

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008526056

Country of ref document: JP

Ref document number: MX/a/2008/001865

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008020243

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 1200/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 565963

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006280312

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2008000152

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2008109246

Country of ref document: RU

Ref document number: 08026341

Country of ref document: CO

Ref document number: KR

Ref document number: 2006813242

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006280312

Country of ref document: AU

Date of ref document: 20060731

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0614761

Country of ref document: BR

Kind code of ref document: A2